Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

Journal of Diabetes Investigation

Volumn 2, Issue 4, 2011, Pages 280-286

  Seino, Yutaka ^a   Rasmussen, Mads Frederik ^b   Nishida, Tomoyuki ^c   Kaku, Kohei ^d  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b NOVO NORDISK A S   (Denmark)

^c Novo Nordisk Pharma Ltd   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Glucagon like peptide 1 receptor agonist; Liraglutide; Sulfonylurea

Indexed keywords

ALANINE AMINOTRANSFERASE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPLICATION SITE REACTION; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOFT TISSUE DISEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 80053617078     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00103.x     Document Type: Article

References (30)

1. Ministry of health labour and welfare, health service bureau: 2002 investigation report of the actual situation of diabetes mellitus. June 2004.
2. Toft-Nielsen M-B, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3853-3860.
3. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998; 15: 297-303.
4. Kawaki J, Nagashima K, Tanaka J, et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 1999; 48: 2001-2006.
5. Takahashi A, Nagashima K, Hamasaki A, et al. Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic b-cell death in the chronic phase. Diabetes Res Clin Pract 2007; 77: 343-350.
6. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
7. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and a- and b-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194.
8. Harder H, Nielsen L, Thi TDT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27: 1915-1921.
9. Saad MF, An B, Santiago O.; on behalf of the 2072 Study Group. The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with type 2 diabetes. Diabetologia 2002; 45(Suppl 2): A44.
10. Nauck M, Hompesch M, Filipczak R, et al. Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes. Diabetes 2004; 53(Suppl 2): A3.
11. Vilsbøll T, Zdravkovic M, Thi TDL, et al. Liraglutide significantly improves glycaemic control, and lowers body weight without risk of either major or minor hypoglycaemic episodes in subjects with type 2 diabetes. Diabetes 2006; 55(Suppl 1): A27.
12. Gutniak MK, Juntti-Berggren L, Hellström PM, et al. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19: 857-863.
13. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?). Endocrinology 1999; 140: 778-783.
14. Rolin B, Larsen MO, Gotfredsen CF, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases b-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
15. Bregenholt S, Moldrup A, Knudsen LB, et al. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat b-cells. 61st Annual Meeting of the American Diabetes Association, Philadelphia, 2001, A31 (Abstract 125-OR).
16. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 341-347.
17. Kageyama S, Hirao K, Shimizu A, et al. Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long acting human GLP-1 analogue. Endocrinol Diabetol 2007; 24: 95-104.
18. Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 2010; 53: 450-467.
19. Drab SR. Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus. Pharmacotherapy 2009; 29: 43S-54S.
20. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
21. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
22. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
23. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
24. Feinglos MN, Saad MF, Pi-Sunyer FX, et al. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005; 22: 1016-1023.
25. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608- 1610.
26. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.
27. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
28. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates b-cell apoptosis. J Biol Chem 2003; 278: 471-478.
29. Hui H, Nourparvar A, Zhao X, et al. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5¢-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144: 1444-1455.
30. Bregenholt S, Møldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits b-cell apoptosis in vitro. Biochem Biophys Res Commun 2005; 330: 577-584.